Medtronic (MDT) Wells Fargo 21st Annual Healthcare Conference summary

Industry trends and innovation

• MedTech is experiencing robust innovation, with AI and robotics acting as force multipliers to expand patient access, improve outcomes, and lower costs.

• Market expansion is driven by new therapies and lowering treatment thresholds in established segments, pulling in previously untreated patients.

• AI is enabling earlier, more accurate diagnoses and personalized therapies at scale, exemplified by products like GI Genius in colonoscopy.

• Robotics and digital platforms are democratizing care, especially in emerging markets with physician shortages.

• China remains a profitable growth market, with revenue stabilizing post-VBP and continued commitment to the region.

Financial performance and growth drivers

• Q1 saw strong organic growth of 7%, with major franchises like cardiac rhythm management and spine outperforming due to innovation.

• Four high-growth areas—Cardiac Ablation, hypertension (Symplicity), urinary incontinence (Altaviva), and surgical robotics (Hugo)—are multi-billion dollar opportunities.

• Cardiac Ablation business is growing at 2.5x the market rate, with new products like Sphere-360 expected to sustain momentum.

• Renal denervation for hypertension is showing strong clinical results and is expected to become a billion-dollar product.

• Altaviva is revitalizing the pelvic health business by simplifying procedures and expanding the patient base.

Strategic investments and portfolio management

• Significant investments in robotics, including a $700M deal with Cornerstone for rights in 50 countries, support a tiered approach for emerging markets.

• Robotics is seen as a secular trend, with Hugo already impacting surgical business performance and 250 global installations expected by year-end.

• The MiniMed diabetes business is performing strongly, with separation timing expected to have minimal EPS impact.

• M&A activity has accelerated, focusing on tuck-in acquisitions to complement the portfolio, supported by strong cash flow and disciplined capital allocation.